Intended for healthcare professionals


Review of drug subsidy scheme delayed as test case looms

BMJ 2006; 333 doi: (Published 14 December 2006) Cite this as: BMJ 2006;333:1239
  1. Bob Burton
  1. 1Canberra

    A review of the pharmaceuticals provisions of the Australia-United States free trade agreement has been deferred until after the announcement of the outcome of a landmark appeal.

    The appeal by Eli Lilly Australia against the decision not to include the osteoporosis drug teriparatide (Forteo) in the Australian government's Pharmaceutical Benefits Scheme will be decided upon by an independent reviewer and is expected early next year.

    The decision is seen by the drug industry as a test case on the effectiveness of concessions won when the agreement was concluded in 2004 (BMJ 2004;328:604). On four occasions, the company's …

    View Full Text

    Log in

    Log in through your institution


    * For online subscription